Publications of F. Weber

Weber, F.; Fontaine, B.; Cournu-Rebeix, I.; Kroner, A.; Knop, M.; Lutz, S.; Müller-Sarnowski, F.; Uhr, M.; Bettecken, T.; Kohli, M. et al.; Ripke, S.; Ising, M.; Rieckmann, P.; Brassat, D.; Semana, G.; Babron, M. C.; Mrejen, S.; Gout, C.; Lyon-Caen, O.; Yaouanq, J.; Edan, G.; Clanet, M.; Holsboer, F.; Clerget-Darpoux, F.; Müller-Myhsok, B.: IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Journal of Neurology 255 (Suppl. 2), pp. 52 - 53 (2008)

Weber, F.; Fontaine, B.; Cournu-Rebeix, I.; Kroner, A.; Knop, M.; Lutz, S.; Müller-Sarnowski, F.; Uhr, M.; Bettecken, T.; Kohli, M. et al.; Ripke, S.; Ising, M.; Rieckmann, P.; Brassat, D.; Semana, G.; Babron, M. C.; Mrejen, S.; Gout, C.; Lyon-Caen, O.; Yaouanq, J.; Edan, G.; Clanet, M.; Holsboer, F.; Clerget-Darpoux, F.; Müller-Myhsok, B.: IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes and Immunity 9 (3), pp. 259 - 263 (2008)

Kümpfel, T.; Schwan, M.; Pollmächer, T.; Yassouridis, A.; Uhr, M.; Trenkwalder, C.; Weber, F.: Time of interferon- β 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients. Multiple Sclerosis 13 (9), pp. 1138 - 1145 (2007)

Jastorff, A.; Haegler, K.; Maccarrone, G.; Holsboer, F.; Weber, F.; Turck, C.; Ziemssen, T.: Experimental autoimmune encephalomyelitis biomarkers indicate mechanisms mediating neurodegeneration. Multiple Sclerosis 13 (Suppl. 2), p. S250 - S250 (2007)

Dressel, A.; Mirowska-Guzel, D.; Gerlach, C.; Weber, F.: Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta 1a. Acta Neurologica Scandinavica 116 (3), pp. 164 - 168 (2007)

Knop, M.; Jastorff, A.; Vargas, V.; Hornung, J.; Turck, C.; Weber, F.: Protein expression profiling of human glatiramer acetate (GA) and myelin basic protein (MBP) specific T cell lines from a multiple sclerosis (MS) patient and healthy donors. Pharmacopsychiatry 40 (5), p. 245 - 245 (2007)

Knop, M.; Jastorff, A.; Vargas-Leal, V.; Hornung, J.; Turck, C.; Weber, F.: Protein expression profiling of human glatiramer acetate specific T cell lines from a multiple sclerosis patient and healthy donors. Journal of Neurology 254 (Suppl. 3), pp. 189 - 190 (2007)

Mirowska-Guzel, D.; Gromadzka, G.; Vargas-Leal, V.; Kobayashi, A.; Poniatowska, R.; Czlonkowski, A.; Czlonkowska, A.; Weber, F.: MMP-2, MMP-9 and their inhibitors in ischaernic stroke. Gender differences and time course. Journal of Neurology 254 (Suppl. 3), p. 113 - 113 (2007)

Vargas-Leal, V.; Knop, M.; Hornung, J.; Weber, F.: Human antigen specific T cell lines express neurturin, a member of the GDNF family ligands. Journal of Neurology 254 (Suppl. 3), p. 73 - 73 (2007)

Weber, F.: Multiple Sklerose - Therapie schwerer Krankheitsverläufe. Neurotransmitter - (1), pp. 1 - 5 (2007)

Then Bergh, F.; Kümpfel, T.; Schumann, E.; Held, U.; Schwan, M.; Blazevic, M.; Wismüller, A.; Holsboer, F.; Yassouridis, A.; Uhr, M. et al.; Weber, F.; Daumer, M.; Trenkwalder, C.; Auer, D. P.: Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurology 6 (19), doi:10.1186/1471-2377-6-19 (2006)

Dressel, A.; Kolb, A. K.; Elitok, E.; Bitsch, A.; Bogumil, T.; Kitze, B.; Tumani, H.; Weber, F.: Interferon-β1b treatment modulates cytokines in patients with primary progressive multiple sclerosis. Acta Neurologica Scandinavica 114, pp. 368 - 373 (2006)

Dressel, A.; Vogelsang, A.; Brinkmeier, H.; Mäder, M.; Weber, F.: Glatiramer acetate-specific human CD8+ T cells: Increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment. Journal of Neuroimmunology 181, pp. 133 - 140 (2006)

Rosenhagen, M. C.; Schmidt, U.; Weber, F.; Steiger, A.: Combination therapy of lamotrigine and escitalopram may cause myoclonus. Journal of Clinical Psychopharmacology 26 (3), pp. 346 - 347 (2006)

Rosenhagen, M. C.; Schmidt, U.; Winkelmann, J.; Ebinger, M.; Knetsch, I.; Weber, F.: Olanzapine-induced oculogyric crisis. Journal of Clinical Psychopharmacology 26 (4), p. 431 - 431 (2006)

Gottschalk, M.; Kümpfel, T.; Flachenecker, P.; Uhr, M.; Trenkwalder, C.; Holsboer, F.; Weber, F.: Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Archives of Neurology 62 (2), pp. 277 - 280 (2005)

Dressel, A.; Vogelgesang, A.; Peters, S.; Weber, F.: The cytokine pattern of glatiramer acetate reactive CD8+ T cell lines derived from MS patients and healthy volunteers. Clinical Immunology 115 (Suppl. 1), p. S99 - S99 (2005)

Bitsch, A.; Bahner, D.; Wachter, C.; Elitok, E.; Bogumil, T.; Dressel, A.; Polak, T.; Tumani, H.; Weber, F.; Poser, S. et al.; Kitze, B.: Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis. Acta Neurologica Scandinavica 110 (6), pp. 386 - 392 (2004)

Bitsch, A.; Dressel, A.; Meier, K.; Bogumil, T.; Deisenhammer, F.; Tumani, H.; Kitze, B.; Poser, S.; Weber, F.: Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. Journal of Neurology 251 (12), pp. 1498 - 1501 (2004)

Auer, D. R.; Sämann, P. G.; Gottschalk, M.; Schubert, M. I.; Weber, F.: White matter tract injury and the multiple sclerosis functional composite score. Journal of Neurology 251 (Suppl. Suppl. 3), pp. 178 - 179 (2004)